PriceTargets.com logo

Isoray - ISR Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 02/18/2023 12:59 AM ET
+0 (0.00%)
Get New Isoray Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ISR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ISR

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Isoray in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ISR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Isoray. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2021Northland SecuritiesInitiated CoverageOutperform$1.25N/A
2/18/2021Lake Street CapitalInitiated CoverageBuy$3.00N/A
2/10/2021HC WainwrightBoost TargetBuy$1.25 ➝ $2.10N/A
12/16/2020OppenheimerInitiated CoverageOutperform$1.00High
12/15/2020OppenheimerInitiated CoverageOutperform$1.00N/A
11/12/2020HC WainwrightReiterated RatingBuy$1.25N/A
10/20/2020Dawson JamesDowngradeBuy ➝ NeutralN/A
5/15/2020Ascendiant Capital MarketsBoost TargetBuy$1.40 ➝ $1.75N/A
2/12/2020HC WainwrightReiterated RatingBuy$0.70 ➝ $1.25N/A
7/1/2019Dawson JamesInitiated CoverageBuyN/A
5/13/2019HC WainwrightReiterated RatingBuy$0.70N/A
(Data available from 4/18/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Isoray logo
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.37
Low: $0.28
High: $0.42

52 Week Range

Now: N/A

Volume

145,000 shs

Average Volume

290,697 shs

Market Capitalization

$54.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Isoray?

The following Wall Street sell-side analysts have issued reports on Isoray in the last twelve months: StockNews.com.
View the latest analyst ratings for ISR.

What is the current price target for Isoray?

0 Wall Street analysts have set twelve-month price targets for Isoray in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Isoray in the next year.
View the latest price targets for ISR.

What is the current consensus analyst rating for Isoray?

Isoray currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ISR.

What other companies compete with Isoray?

Other companies that are similar to Isoray include InspireMD, Sensus Healthcare, Health Sciences Acquisitions Co. 2, Autonomix Medical and SEP Acquisition. Learn More about companies similar to Isoray.

How do I contact Isoray's investor relations team?

Isoray's physical mailing address is 350 HILLS STREET SUITE 106, RICHLAND WA, 99354. The company's listed phone number is (509) 375-1202 and its investor relations email address is [email protected]. The official website for Isoray is isoray.com. Learn More about contacing Isoray investor relations.